Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib plus TAS-102 vs fruquintinib in metastatic colorectal cancer after standard treatment failure
ChiCTR2100047021Phase 4Recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in colorectal cancer (CRC) comparing fruquintinib + TAS-102 with Control: fruquintinib monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Sep 2021; status: recruiting.
02
Drugs
fruquintinibtrifluridine + tipiracil
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100047021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047021.